Literature DB >> 23798618

Comparison of PR3-ANCA specific assay performance for the diagnosis of granulomatosis with polyangiitis (Wegener's).

Antonella Radice, Laura Bianchi, Umberto Maggiore, Augusto Vaglio, Renato A Sinico.   

Abstract

BACKGROUND: PR3-ANCA, the serological marker of granulomatosis with polyangiitis (GPA), is usually detected by immunometric assays, with purified PR3 directly coated onto the solid-phase. Novel methods for PR3-ANCA detection have been developed to improve the performance of traditional PR3-ANCA specific assays, but little is known about their diagnostic performance in real-life clinical settings. This study aimed to compare the performance of nine different commercial PR3-ANCA specific assays, including traditional and newer ones, for the diagnosis of GPA.
METHODS: The evaluated assays for PR3-ANCA detection were representative of the first, second, and third generation tests (direct, capture and anchor assays, respectively). A third-generation assay employing both human and recombinant PR3 was also evaluated. The study population consisted of 55 GPA patients, 175 disease controls (representing most diseases in differential diagnosis with primary small-vessel vasculitis) including 52 with microscopic polyangiitis, and 20 healthy subjects. We performed the primary evaluation of test sensitivity using cut-off points which provided adequate and identical specificity for each test.
RESULTS: Although specificity and area under the ROC curve did not differ significantly between the different assays, substantial differences in sensitivity at 98%-specificity were found in some instances (p<0.001). Compared to first generation direct PR3-ANCA specific assays, some of the second and third generation tests increased the positive predictive value (PPV) for GPA diagnosis.
CONCLUSIONS: Some of the newer PR3-ANCA specific assays have better PPV than traditional ones.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23798618     DOI: 10.1515/cclm-2013-0308

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  6 in total

Review 1.  [S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis].

Authors:  Jan Henrik Schirmer; Peer M Aries; Kirsten de Groot; Bernhard Hellmich; Julia U Holle; Christian Kneitz; Ina Kötter; Peter Lamprecht; Ulf Müller-Ladner; Eva Reinhold-Keller; Christof Specker; Michael Zänker; Frank Moosig
Journal:  Z Rheumatol       Date:  2017-11       Impact factor: 1.372

Review 2.  Current and emerging techniques for ANCA detection in vasculitis.

Authors:  Elena Csernok; Frank Moosig
Journal:  Nat Rev Rheumatol       Date:  2014-06-03       Impact factor: 20.543

3.  Simultaneous comprehensive multiplex autoantibody analysis for rapidly progressive glomerulonephritis.

Authors:  Mandy Sowa; Barbara Trezzi; Rico Hiemann; Peter Schierack; Kai Grossmann; Juliane Scholz; Valentina Somma; Renato Alberto Sinico; Dirk Roggenbuck; Antonella Radice
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 4.  Novel clinical and diagnostic aspects of antineutrophil cytoplasmic antibodies.

Authors:  Johannes Schulte-Pelkum; Antonella Radice; Gary L Norman; Marcos Lόpez Hoyos; Gabriella Lakos; Carol Buchner; Lucile Musset; Makoto Miyara; Laura Stinton; Michael Mahler
Journal:  J Immunol Res       Date:  2014-06-05       Impact factor: 4.818

5.  Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA.

Authors:  Mandy Sowa; Kai Grossmann; Ilka Knütter; Rico Hiemann; Nadja Röber; Ursula Anderer; Elena Csernok; Dimitrios P Bogdanos; Maria Orietta Borghi; Pier Luigi Meroni; Peter Schierack; Dirk Reinhold; Karsten Conrad; Dirk Roggenbuck
Journal:  PLoS One       Date:  2014-09-16       Impact factor: 3.240

6.  Serum ANCA and Overall Mortality: A 10-Year Retrospective Cohort Study on 1,024 Italian Subjects.

Authors:  Enrico Brunetta; Giacomo Ramponi; Marco Folci; Maria De Santis; Emanuela Morenghi; Elena Vanni; Elena Bredi; Raffaello Furlan; Claudio Angelini; Carlo Selmi
Journal:  Front Immunol       Date:  2021-09-10       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.